- Cardioascular effect of incretin-based therapies: comparison od DPP-4 inhibitors and GLP-1 agonists2014 | First Faculty of Medicine
- Incretin-based therapies of diabetes2009 | First Faculty of Medicine
- The expanding role of incretin-based therapies: how much should we expect?2014 | First Faculty of Medicine
- Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights2020 | First Faculty of Medicine
- Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects2014 | First Faculty of Medicine
- Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections2022 | First Faculty of Medicine
- Instead of incretin-based therapy in the current strategy of pharmacological treatment of type 2 diabetes2008 | Second Faculty of Medicine
- Contemporary state and perspectives of obesity pharmacotherapy2020 | First Faculty of Medicine
- Knowledge about GLP-1 based therapies changed the possibilities of diabetes treatment, but its use could be much broader2011 | Third Faculty of Medicine
- Incretin-based treatment of diabetes and cardiovascular complications2020 | First Faculty of Medicine
- News in the treatment of diabetes2011 | First Faculty of Medicine
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus2013 | First Faculty of Medicine
- Pathophysiological basis of incretin therapies: can it be even more effective than we think?2011 | First Faculty of Medicine
- The effect of newer antidiabetic drugs on the weight of patients with type 2 diabetes2010 | First Faculty of Medicine
- Experiences with vildagliptin in the treatment of patients with type 2 diabetes mellitus2012 | First Faculty of Medicine
- Linagliptin: a new interesting molecule in therapy of type 2 diabetes mellitus2012 | First Faculty of Medicine
- Cardiovascular effects of glukagon-like peptide-1 and its agonist: more than just cardiovascularly safe antidiabetics?2012 | First Faculty of Medicine
- Antidiabetic drugs and cardiovascular risk - before and now2012 | First Faculty of Medicine
- Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria2013 | First Faculty of Medicine, Third Faculty of Medicine
- Role of incretins in energy metabolism and weight changes after smoking cessation2016 | First Faculty of Medicine
- Current treatment options for type 2 diabetes2008 | Second Faculty of Medicine
- Delaying vascular complications of diabetes2014 | First Faculty of Medicine
- Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide2015 | First Faculty of Medicine
- Physiological secretion of GLP-1 (glucagon-like peptide-1)2015 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Gut as an emerging organ for the treatment of diabetes: focus on mechanism of action of bariatric and endoscopic interventions2018 | First Faculty of Medicine